Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.63 Bil Enterprise Value: 14.68 Bil PE Ratio: 71.95 PB Ratio: 2.88 GF Score: 71/100

Biomarin Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 05:15PM GMT
Release Date Price: $78.61 (+0.14%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have BioMarin with us for the next session. Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So with that, I'm going to turn it over to J.J. Bienaime, the CEO, to make some opening remarks, and then we'll jump into Q&A.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you, Matthew, and we appreciate the opportunity to speak with you today. So starting with our most recent commercial product, VOXZOGO, for the treatment of children with achondroplasia. We were thrilled to announce 2 weeks ago that the European Commission granted approval for children ages

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot